Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929 | 1.00 | ACHE (0.66) | ACHESLC6A3SIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL11205656 | 1.00 | ACHE (0.66) | ACHESLC6A3SIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL7979173 | 0.91 | L3MBTL1 (0.62) | SIGMAR1HRH3 | |
| SCHEMBL19850993 | 0.91 | L3MBTL1 (0.62) | SIGMAR1HRH3 | |
| SCHEMBL14197718 | 0.90 | ACHE (0.81) | ACHESLC6A3SIGMAR1HRH3CYP3A4 | |
| SCHEMBL14106253 | 0.90 | ACHE (0.81) | ACHESLC6A3SIGMAR1HRH3CYP3A4 | |
| SCHEMBL491602 | 0.84 | HRH3 (0.68) | HRH3 | |
| SCHEMBL12717 | 0.83 | CYP3A4 (0.66) | ACHESIGMAR1HPGDSMN1; SMN2HRH3 | |
| SCHEMBL5304179 | 0.83 | CYP3A4 (0.66) | ACHESIGMAR1HPGDSMN1; SMN2HRH3 | |
| SCHEMBL13083 | 0.83 | CYP3A4 (0.66) | ACHESIGMAR1HPGDSMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | ACHE 2535/4885SLC6A3 3718/4885SIGMAR1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.